Search - tctmd.com

Displaying 21 - 40 of 84

Sort: Relevancy | Date

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

News Daily News

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

November 01, 2022

RAPID: Positive Top-line Results for Etripamil Nasal Spray in Paroxysmal SVT

News Daily News

RAPID: Positive Top-line Results for Etripamil Nasal Spray in Paroxysmal SVT

October 17, 2022

TCT 548: Impact of Cardiovascular Diseases, Calcium Channel Blockers, and Beta-Blockers on Two-Year Mortality of Patients with COVID-19: A Single-Center Retrospective Analysis

Presentation TCT 2022

TCT 548: Impact of Cardiovascular Diseases, Calcium Channel Blockers, and Beta-Blockers on Two-Year Mortality of Patients with COVID-19: A Single-Center Retrospective Analysis

Presenter: Rashid Alhusain

September 18, 2022

Certain CV Meds Tied to Higher MI Risk in Warmer Weather

News Daily News

Certain CV Meds Tied to Higher MI Risk in Warmer Weather

August 04, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

News Conference News ACC 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

April 02, 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA

News Daily News

Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA

Yael L. Maxwell

January 27, 2022

‘Enormous’ QoL Improvements With Mavacamten in HCM

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

May 15, 2021

Skin Cancer Risk With Common Diuretics Confirmed Anew

News Daily News

Skin Cancer Risk With Common Diuretics Confirmed Anew

April 14, 2021

ACE Inhibitors, ARBs: Still No Link to COVID-19 Risks, New Analyses Show

News Daily News

ACE Inhibitors, ARBs: Still No Link to COVID-19 Risks, New Analyses Show

Michael O'Riordan

December 21, 2020

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

News Conference News ESC 2020

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

September 04, 2020

GATEWAY at 3 Years: Bariatric Surgery Continues to Reduce Need for Antihypertensive Drugs

News Daily News

GATEWAY at 3 Years: Bariatric Surgery Continues to Reduce Need for Antihypertensive Drugs

August 31, 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

Higher Risk of HF After ACS for Women Previously on Beta-blockers

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

News Daily News

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

January 21, 2020

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

October 23, 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

News Conference News ESC 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

August 31, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.